Sunday, November 22, 2026Every story links to its original source.

Genome News

Genomics news, traced to the source.

Reading

study2 min read

ANGPTL3 gene editing lowered blood lipids in animal models

Illustrative photo by Mikhail Nilov, Pexels LicenseImage licenceFull-size image

Inactivating the ANGPTL3 gene was associated with reductions of approximately 40 to 50% in LDL-C and 50 to 70% in triglycerides in mouse and nonhuman primate models of high blood lipids. The study, published in Nature, included investigators from Verve Therapeutics, Inc. and the University of Pennsylvania. In nonhuman primates, a single dose reduced circulating ANGPTL3 protein by a mean of > 90%, with the reduction confirmed out to 3 years after treatment. The findings supported the initiation of an ongoing first-in-human clinical trial.

The treatment targets ANGPTL3, a gene whose protein drives increased levels of LDL-C, or low-density lipoprotein cholesterol, and triglycerides. The researchers described it as a potential single-course treatment: an infusion that selectively inactivates the gene in the liver.

The infusion carries mRNA, instructions for making a CRISPR adenine base editor, along with guide RNA that directs the editor to its target. The editor makes a change to a DNA base pair, part of the genetic code. A tiny fat-based carrier called a lipid nanoparticle encloses these components for delivery to the liver.

In human liver cells grown in the laboratory, the researchers confirmed a DNA base-pair change at the intended ANGPTL3 location. They detected no editing outside the target at any of approximately 3000 candidate sites. They also found no treatment-related structural variants, which are changes in the arrangement of DNA. Targeted gene inactivation was well tolerated in nonhuman primates.

The ongoing clinical trial is testing the approach in patients with refractory hyperlipidemia syndromes, conditions in which high blood lipid levels remain difficult to control despite treatment. The lipid reductions reported in the study were measured in mice and nonhuman primates. The analyses of human liver cells were carried out in the laboratory, rather than in patients.

LDL-C and triglyceride-rich lipoproteins are leading risk factors for atherosclerotic cardiovascular disease, which involves fatty buildup in arteries. Several lipid-lowering medications are approved, but most patients do not reach target lipid levels with ongoing treatment.

Written by the Genomes desk from the primary source cited and linked above and checked against it. Research use only; not medical advice. Corrections: [email protected].

More from the archive

Back to the latest · Archive